Ona Therapeutics

Ona Therapeutics is a private, pre-clinical stage biotech focused on developing novel antibody drug conjugates (ADCs) for metastatic and refractory cancers. The company's core strategy is to identify unique therapeutic targets by analyzing the molecular changes in cancers from patients who have become resistant to standard treatments, thereby addressing a critical unmet need. With a seasoned leadership team and backing from a €30M Series A round, Ona is advancing two wholly-owned internal programs, including a lead ADC for refractory breast cancer. The company represents a targeted approach in the competitive ADC landscape, aiming to improve outcomes for advanced cancer patients.

Biology-first platform that discovers novel therapeutic targets by analyzing molecular changes in cancers from treatment-refractory patients, coupled with expertise in designing and engineering precision antibody drug conjugates (ADCs).

Ona operates in the highly competitive antibody drug conjugate (ADC) field, competing with large pharma (e.g., AstraZeneca, Pfizer, Gilead) and numerous biotechs. Its differentiation lies in its unique target discovery approach focused on refractory patient biology, rather than competing on well-known antigens. However, it must demonstrate superior efficacy or safety to gain market share against established and emerging ADC therapies.